CA-VENTURE-REALITY-FUND
Silicon Valley-based venture firm The Venture Reality Fund (The VR Fund) today released its first-ever European virtual reality (VR) landscape, featuring dozens of companies developing infrastructure, tools/platforms and/or apps for the booming ecosystem. The landscape was created in partnership with LucidWeb , the French VR and WebVR consulting and development agency, to depict the growth in the ecosystem, increased investment and growing international impact.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170207005665/en/
The European VR landscape is based on extensive research and information gathered during meetings and calls with regional VR ambassadors across Europe. Close to 300 VR startups were identified and reviewed, of which 116 were selected to be part of the first release of the VR Landscape Europe.
“We chose to partner with LucidWeb as they have a strong database of top VR startups in Europe and valuable familiarity with the European ecosystem,” says Tipatat Chennavasin, co-founder and general partner at The Venture Reality Fund. “These landscapes are a visual representation of our commitment to education and growth of the industry.”
Highlights from the European VR landscape include:
- The VR gaming industry remains the most competitive space with well-funded companies including CCP Games (Iceland), nDreams (United Kingdom), Resolution Games (Sweden) and Solfar Studios (Iceland).
- User input technology, focused on interactions in VR by brain (BCI), body, eye, feet and hand, has many premium players, such as the Swiss-based company Mindmaze that raised $100 million, the largest amount raised in one round by any European VR company.
- Reality capture concentrated on 360° video hardware, 360° video software and next generation technology (photogrammetry), is prominent with two French-based companies, VideoStitch and Giroptic, at the forefront.
- Enterprise is gaining traction with real estate VR generating significant additional revenue for online agencies across Europe. Swedish-based Diakrit and Dutch company TheConstruct are two companies leading the charge.
- French company Homido, Mindmaze and Swedish-based company Starbreeze are the most advanced hardware companies developing a mobile Head Mounted Display (HMD) or tethered HMD.
- Companies in post-production of VR are developing 3D tools, which leading American software companies have acquired over the past two years: Google acquired Irish Thrive Audio; Facebook acquired Scotland-based Two Big Ears; and Snapchat acquired London-based Seen/Obvious Engineering.
- Healthcare and fitness companies are utilizing VR for medical training, mental treatments (anxiety, Asperger’s syndrome) and physical rehabilitation. Spanish-based Psious and Amsterdam-based MDLinking are two companies to watch in this category.
- More than half of the companies included in the landscape are based in United Kingdom, France, Germany and Sweden.
- France is taking the lead in VR in continental Europe.
“The VR industry is booming and not just in the US or Asia. The old continent has known a slower start, but definitely got up to speed during the past two years,” says Leen Segers, co-founder and CEO at LucidWeb. “The VR gaming segment remains the most competitive space, but is surely challenged by a large number of companies focusing on user input or 3D tools. We feel very excited for the future as we see local and international investors are clearly investing in these segments, too.”
| The VR Fund European Landscape in collaboration with LucidWeb | ||||||||||||
|
United
|
BBC Taster, Bossa Studios, Climax Studios, Coatsink, Curiscope, Framestore, Future Lighthouse, Hammerhead VR, Immersive Rehab, Immersive VR Education, Improbable, Medical Realities, Mel Science, NCTech Imaging, nDreams, Neurable, SkyVR, Sony London Studios, Starship Group (vTime), Tammeka, The Foundry, Thomas Cook, Ultrahaptics, Ustwoo, Virzoom, Zero Light | Finland (3) | Nokia, Umbra, Vizor | |||||||||
| France (19) | 3D Rudder, Archos, Arte360, Giroptic, Holodia, Homido, Immersion, Innerspace, LucidWeb, MiddleVR, Okio, Revinax, Simforheatlh, TechViz, Teemew, Ubisoft, Unimersiv, V-cult, Videostitch/Orah |
Czech
|
Keen VR, Solirax, Sphericam | |||||||||
| Germany (11) | Crytek, Fraunhouser IPK, Gestigon, Inflight VR, realities.io, Sennheiser, SMI, Splash, Vire, WearVR, Zeiss | Belgium (2) | Around Media, Mimesys | |||||||||
| Sweden (9) | Diakrit, Manomotion, Mojang, Resolution games, Starbreeze, Svrvive, Thinglink, Tobii, UniVrses | Austria (2) | Cyberith, Red Bull Media | |||||||||
|
The
|
Forcefield VR, Headjack, Manus Machina, MDLinking, Smart2VR, TheConstruct | Norway (2) | Making View, The Moon | |||||||||
| Russia (6) | 3DiVi, Agisoft Photoscan, Cerevrum, Fibrum, Gaijn Entertainment, Luden.io | Estonia (2) | Criffin, Wolfprint | |||||||||
| Iceland (4) | Aldin Dynamics, Breakroom/MureVR, CCP Games, Solfar Studios | Denmark (2) | Labster, Unity 3D | |||||||||
| Switzerland (3) | Casino VR, Mindmaze, Virtamed | Croatia (2) | Croteam, Spacesys | |||||||||
| Spain (3) | ImmersiON-VRelia, NeuroDigital Technologies, Psious | Ireland (2) | Artomatix, Immersive VR Education | |||||||||
| Italy (3) | inVRsion, Oniride, Remoria | Latvia (2) | Giraffe360, Vividly | |||||||||
| Belarus : MMone; Hungary : Zlense; Slovakia : Capturing Reality; Poland : Shapespark | ||||||||||||
The VR Fund releases updated VR and AR industry landscapes quarterly, which can be found under the Resources tab of The Venture Reality Fund’s site.
About The Venture Reality Fund
The Venture Reality Fund (The
VR Fund) is a Silicon Valley-based venture capital firm focused on
early-stage investments in the virtual reality (VR), augmented reality
(AR) and mixed reality (MR) spaces. As a founding member of the Virtual
Reality Venture Capital Alliance (VRVCA), The VR Fund invests globally
in innovative companies across a wide variety of sectors from
infrastructure and development tools to content and applications, to
help entrepreneurs bring industry-defining technology to market faster.
For more information, please visit TheVRFund.com , like The VR Fund on Facebook and follow on LinkedIn and Twitter .
About LucidWeb
LucidWeb is a VR and WebVR consulting and
software development company. LucidWeb offers consulting services
(inspirational and/or technical ateliers), next to offering a premium
distribution platform based upon the WebVR technology called "reVeRies
Pro", targeting content creators/publishers/enterprises. LucidWeb
combines 15 years of European business expertise and technical know-how.
The company uses this accumulated experience to pioneer and push the
boundaries of (commercial) virtual reality.
For more information,
please visit LucidWeb.io
,
like LucidWeb on Facebook
and follow on Twitter
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170207005665/en/
Contact:
For The Venture Reality Fund
Lisa Inouye, (310) 777-7546
lisa@pmbcgroup.com
or
Ashley
Ray,(310) 777-7546
ashley@pmbcgroup.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom